ATE377418T1 - Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen - Google Patents

Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen

Info

Publication number
ATE377418T1
ATE377418T1 AT96921577T AT96921577T ATE377418T1 AT E377418 T1 ATE377418 T1 AT E377418T1 AT 96921577 T AT96921577 T AT 96921577T AT 96921577 T AT96921577 T AT 96921577T AT E377418 T1 ATE377418 T1 AT E377418T1
Authority
AT
Austria
Prior art keywords
sup
sub
alkyl
beta
tgf
Prior art date
Application number
AT96921577T
Other languages
English (en)
Inventor
David J Grainger
James C Metcalfe
Lawrence L Kunz
Paul R Kemp
Robert W Schroff
Peter L Weissberg
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,393 external-priority patent/US6395494B1/en
Priority claimed from US08/486,334 external-priority patent/US5770609A/en
Priority claimed from US08/476,735 external-priority patent/US5595722A/en
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE377418T1 publication Critical patent/ATE377418T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
AT96921577T 1995-06-07 1996-06-07 Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen ATE377418T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47893695A 1995-06-07 1995-06-07
US08/477,393 US6395494B1 (en) 1993-05-13 1995-06-07 Method to determine TGF-β
US08/486,334 US5770609A (en) 1993-01-28 1995-06-07 Prevention and treatment of cardiovascular pathologies
US08/476,735 US5595722A (en) 1993-01-28 1995-06-07 Method for identifying an agent which increases TGF-beta levels

Publications (1)

Publication Number Publication Date
ATE377418T1 true ATE377418T1 (de) 2007-11-15

Family

ID=27504217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921577T ATE377418T1 (de) 1995-06-07 1996-06-07 Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen

Country Status (7)

Country Link
US (3) US6197789B1 (de)
EP (1) EP0833624B1 (de)
JP (1) JPH11510479A (de)
AT (1) ATE377418T1 (de)
AU (1) AU6277396A (de)
CA (1) CA2223595C (de)
WO (1) WO1996040098A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162587C (en) * 1993-05-13 2008-07-08 Kunz, Lawrence Leroy Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6432982B1 (en) * 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US20070142901A1 (en) * 1998-02-17 2007-06-21 Steinke Thomas A Expandable stent with sliding and locking radial elements
US6623521B2 (en) 1998-02-17 2003-09-23 Md3, Inc. Expandable stent with sliding and locking radial elements
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
JP4712975B2 (ja) 1999-01-12 2011-06-29 ケンブリッジ エンタープライズ リミティド 炎症反応を阻害又は増強するための組成物及び方法
US6649352B1 (en) 1999-01-29 2003-11-18 Center For Molecular Medicine And Immunology Method of evaluating myelosuppressive state
US7112409B2 (en) 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
US7393864B2 (en) * 1999-02-26 2008-07-01 University Of Iowa Research Foundation Use of ClC3 chloride channel blockers to modulate vascular tone
US7220782B1 (en) * 1999-02-26 2007-05-22 University Of Iowa Research Foundation Methods to reduce the sensitivity of endothelially-compromised vascular smooth muscle
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20050003455A1 (en) * 2001-08-08 2005-01-06 Yasunobu Okada Remedies for heart diseases
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
US6908460B2 (en) 2001-08-28 2005-06-21 Joseph Distefano Apparatus for conveying a light source to an intravenous needle to kill blood pathogens
US20050106138A1 (en) * 2001-09-18 2005-05-19 Hamid Rabb Specific depletion of cd4+ t cells
JP3990972B2 (ja) * 2001-11-20 2007-10-17 有限会社 キック 血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
US6951053B2 (en) * 2002-09-04 2005-10-04 Reva Medical, Inc. Method of manufacturing a prosthesis
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
US7196119B2 (en) 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
US7763065B2 (en) * 2004-07-21 2010-07-27 Reva Medical, Inc. Balloon expandable crush-recoverable stent device
US20060088571A1 (en) * 2004-10-21 2006-04-27 Medtronic Vascular, Inc. Biocompatible and hemocompatible polymer compositions
US8292944B2 (en) * 2004-12-17 2012-10-23 Reva Medical, Inc. Slide-and-lock stent
US7914574B2 (en) * 2005-08-02 2011-03-29 Reva Medical, Inc. Axially nested slide and lock expandable device
US9149378B2 (en) 2005-08-02 2015-10-06 Reva Medical, Inc. Axially nested slide and lock expandable device
US20070231361A1 (en) * 2006-03-28 2007-10-04 Medtronic Vascular, Inc. Use of Fatty Acids to Inhibit the Growth of Aneurysms
US7704275B2 (en) * 2007-01-26 2010-04-27 Reva Medical, Inc. Circumferentially nested expandable device
EP2211773A4 (de) 2007-11-30 2015-07-29 Reva Medical Inc Axial-radial verschachtelte expandierbare vorrichtung
EP2331014B1 (de) 2008-10-10 2017-08-09 Reva Medical, Inc. Dehnbarer schieber und verschlussstent
KR20110039842A (ko) * 2009-10-12 2011-04-20 주식회사 바이오씨에스 이미다졸 화합물을 유효성분으로 포함하는 안구의 혈관 신생 관련 질환의 예방 및 치료용 조성물
GB2475907A (en) 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
JP5809237B2 (ja) 2010-04-10 2015-11-10 レヴァ メディカル、 インコーポレイテッドＲｅｖａ Ｍｅｄｉｃａｌ， Ｉｎｃ． 拡張可能なスライドロックステント
JP6343147B2 (ja) 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
KR101564059B1 (ko) 2011-12-27 2015-10-30 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
US9408732B2 (en) 2013-03-14 2016-08-09 Reva Medical, Inc. Reduced-profile slide and lock stent
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CA3032153A1 (en) * 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
NL224562A (de) 1957-02-05
US3168565A (en) 1959-11-20 1965-02-02 Richardson Merrell Inc Trifluoromethyl derivatives of amino triarylethanols, -ethanes, and -ethylenes
GB1015787A (en) 1962-08-03 1966-01-05 Giuseppe Carlo Sigurta Tris-(p-methoxyphenyl)ethylene derivatives
BE637389A (de) 1962-09-13
US3288806A (en) 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
US3634517A (en) 1968-08-19 1972-01-11 Richardson Merrell Inc Triarylalkenones
US5521171A (en) 1975-03-31 1996-05-28 Sorenson; John R. J. Anti-inflammatory and anti-ulcer compounds and process
JPS5640710B2 (de) 1973-01-18 1981-09-22
US4070484A (en) 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4323707A (en) 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
US4235988A (en) 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
US4239778A (en) 1978-09-12 1980-12-16 The University Of Illinois Foundation Azaprostanoic acid analogs and their use as inhibitors of platelet aggregation
EP0019377B1 (de) 1979-05-15 1982-08-04 Imperial Chemical Industries Plc 1-Hydrocarbyloxyphenyl-1.2-diphenylalken-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzung
US4879315A (en) 1982-03-30 1989-11-07 The Board Of Regents For The University Of Oklahoma Cyclopropyl analogs as anti-estrogenic, anti-tumor and female fertility agents
US5658927A (en) 1980-03-07 1997-08-19 Research Corporation Technologies Diphenylcyclopropyl analogs
US5098903A (en) 1980-03-07 1992-03-24 Board Of Regents Of The University Of Oklahoma Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
US5324736A (en) 1980-03-07 1994-06-28 Research Corporation Technologies, Inc. Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
US4442119A (en) 1980-07-07 1984-04-10 The Board Of Regents For The University Of Oklahoma Cyclopropyl analogs as estrogenic and anti-fertility agents
US4956129A (en) 1984-03-30 1990-09-11 Ici Americas Inc. Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5015666A (en) 1982-03-30 1991-05-14 Board of Reagents of the University of Oklahoma Triarylcyclopropanes as antiestrogens and antitumor agents
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4512762A (en) 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
US5226430A (en) 1984-10-24 1993-07-13 The Beth Israel Hospital Method for angioplasty
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4824436A (en) 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US4826672A (en) 1985-06-07 1989-05-02 President And Fellows Of Harvard College Astatinated organic compounds
DE3544663A1 (de) 1985-12-13 1987-06-19 Schering Ag Thrombosebehandlung mit fibrinolytika und prostacyclinen
US5120535A (en) 1986-11-26 1992-06-09 Oncogen Oncostatin M and novel compositions having anti-neoplastic activity
US4859585A (en) 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5314679A (en) 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
EP0260066B1 (de) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifenderivate
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP2564386B2 (ja) 1987-04-16 1996-12-18 クリスチャン ビンチャエドラー 水不溶性ポリマーの粉末の調整方法
EP0287690B1 (de) 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5114719A (en) 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5527337A (en) 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US4835002A (en) 1987-07-10 1989-05-30 Wolf Peter A Microemulsions of oil in water and alcohol
US5221620A (en) 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
DE3737340A1 (de) 1987-11-04 1989-05-24 Bayer Ag Neue fluormethoxyphenyl-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
US4929602A (en) 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
DE3821544C2 (de) 1988-06-25 1994-04-28 H Prof Dr Med Just Dilatationskatheter
US5468746A (en) 1988-07-29 1995-11-21 Zambon Group S.P.A. Compounds active on the cardiovascular system
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
CA2002011A1 (en) 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5304541A (en) 1988-12-15 1994-04-19 Bristol-Myers Squibb Company Methods using novel chimeric transforming growth factor-β1/β2
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5284869A (en) 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5356630A (en) 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
FR2645160B1 (de) 1989-03-31 1992-10-02 Rhone Poulenc Chimie
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5026537A (en) 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
US4994033A (en) 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5248764A (en) 1989-06-16 1993-09-28 Merck Frosst Canada, Inc. Chelate derivatives of atrial natriuretic factor (ANF)
HU212760B (en) 1989-06-20 1997-02-28 Denes Method and device for the apportion of chemical materials into the vein wall
US5242397A (en) 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
US5009659A (en) 1989-10-30 1991-04-23 Schneider (Usa) Inc. Fiber tip atherectomy catheter
US5176617A (en) 1989-12-11 1993-01-05 Medical Innovative Technologies R & D Limited Partnership Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5059166A (en) 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5199939B1 (en) 1990-02-23 1998-08-18 Michael D Dake Radioactive catheter
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5166143A (en) 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
CA2081896A1 (en) 1990-06-15 1991-12-16 James E. Shapland Drug delivery apparatus and method
US5401730A (en) 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5189046A (en) 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5219548A (en) 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5238714A (en) 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5053033A (en) 1990-10-10 1991-10-01 Boston Advanced Technologies, Inc. Inhibition of restenosis by ultraviolet radiation
US5180366A (en) 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
KR930006431B1 (ko) 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
AU660635B2 (en) * 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
EP0565620B1 (de) 1991-01-03 1995-09-20 The Salk Institute For Biological Studies Mitotoxin zur behandlung von gefässbeschädigung
US5102402A (en) 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5116864A (en) 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5458568A (en) 1991-05-24 1995-10-17 Cortrak Medical, Inc. Porous balloon for selective dilatation and drug delivery
US5213576A (en) 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
CA2070243A1 (en) 1991-06-14 1992-12-15 Akira Shiozawa Chroman derivatives
US5229495A (en) 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5216126A (en) 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
US5250561A (en) * 1991-08-08 1993-10-05 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors
US5185260A (en) 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
AU2738392A (en) 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5304325A (en) 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5270047A (en) 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
WO1993013660A1 (en) 1992-01-06 1993-07-22 Health Maintenance Programs, Inc. Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
DE69309435T2 (de) 1992-01-17 1997-07-10 Daiichi Seiyaku Co Restenosehemmer nach perkutaner koronarer arterioplastie
ATE146359T1 (de) 1992-01-21 1997-01-15 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
US5280109A (en) 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
CA2087132A1 (en) 1992-01-31 1993-08-01 Michael S. Williams Stent capable of attachment within a body lumen
US5444164A (en) 1992-02-05 1995-08-22 Bristol-Myers Squibb Company TGF-β induced gene
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
JP2617407B2 (ja) 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5344887A (en) 1992-12-21 1994-09-06 Shell Oil Company Star polymers of dienes, vinylarenes and alkyl methacrylates as modiied viscosity index improvers
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
GB2273873A (en) 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
US5354774A (en) 1992-12-24 1994-10-11 Yale University Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE4401554A1 (de) 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
DE4320898A1 (de) 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
DE4320896A1 (de) 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen
TW303299B (de) 1993-07-22 1997-04-21 Lilly Co Eli
US5354801A (en) 1993-08-12 1994-10-11 Cytec Technology Corp. Process for producing small polymer phase droplet microemulsions by multistep aqueous phase addition
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5482950A (en) 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5441964A (en) 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
UA32427C2 (uk) 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US5391557A (en) 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5457113A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5457116A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5418252A (en) 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5480904A (en) 1993-10-28 1996-01-02 Eli Lilly And Company Methods for inhibiting uterine fibrosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5393772A (en) 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5447941A (en) 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5446053A (en) 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5439931A (en) 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5521198A (en) 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
TW427902B (en) 1993-12-21 2001-04-01 Lilly Co Eli Pharmaceutical composition for inhibiting low-density lipoprotein (LDL) oxidation and atherosclerosis
US5439923A (en) 1993-12-21 1995-08-08 Eli Lilly And Company Method of inhibiting seborrhea and acne
US5574047A (en) 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5552415A (en) 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5389670A (en) 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5519042A (en) 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5407955A (en) 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
BR9500758A (pt) 1994-03-02 1995-10-24 Lilly Co Eli Formulaçoes farmacêuticas para administraçao oral
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5455275A (en) 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5384332A (en) 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5470883A (en) 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US5424331A (en) 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
US5466810A (en) 1994-06-10 1995-11-14 Eli Lilly And Company 2-amino-3-aroyl-benzo[β]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)-benzoyl]benzo[β]thiophenes
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5434166A (en) 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
US5491159A (en) 1994-08-30 1996-02-13 American Home Products Corporation 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US6399634B1 (en) 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US5521191A (en) 1994-10-17 1996-05-28 Washington University Method for treatment of arterial stenosis
US5516807A (en) 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
US5498775A (en) 1994-11-07 1996-03-12 American Home Products Corporation Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation
US5489587A (en) 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5484808A (en) 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5563054A (en) 1995-03-31 1996-10-08 Eli Lilly And Company Process for preparation of benzo[B]thiophene glucuronides
US5622975A (en) 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US5639274A (en) 1995-06-02 1997-06-17 Fischell; Robert E. Integrated catheter system for balloon angioplasty and stent delivery
US5726186A (en) 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies

Also Published As

Publication number Publication date
US20060135560A1 (en) 2006-06-22
US20020068731A1 (en) 2002-06-06
CA2223595C (en) 2008-08-05
EP0833624A2 (de) 1998-04-08
CA2223595A1 (en) 1996-12-19
US6197789B1 (en) 2001-03-06
EP0833624B1 (de) 2007-11-07
WO1996040098A2 (en) 1996-12-19
WO1996040098A3 (en) 1997-06-19
AU6277396A (en) 1996-12-30
JPH11510479A (ja) 1999-09-14

Similar Documents

Publication Publication Date Title
ATE377418T1 (de) Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
GB9930610D0 (en) Tricyclic vascular damaging agents
RU97115713A (ru) Соединения, содержащие бензопиран и способ их применения
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
RU99110944A (ru) Тиенопиримидины с ингибирующим действием по отношению к фосфодиэстеразе v (pde v)
KR890701587A (ko) 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리
NO810479L (no) Fremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazolderivater
RU94044454A (ru) Ингибитор аутоимунных заболеваний
TNSN04212A1 (fr) Sels de tolterodine
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ES2045189T3 (es) Nuevos agentes anti-arritmicos i.
DE69533194D1 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
ES2053668T3 (es) Derivados de poliamina como agentes antineoplasicos.
EA200100791A1 (ru) Ингибиторы аминотрансфераз, зависимых от аминокислот с разветвленной цепью, и их применение в лечении диабетической ретинопатии
EA199800013A1 (ru) Способы минимизации остеопороза
EA200200121A1 (ru) Замещенные производные пурина в качестве ингибиторов клеточной адгезии
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
KR960703924A (ko) 항바이러스제로서 신규한 벤조티오펜 유사체(Novel Benzothiophene Analogs as Antiviral Agents)
KR940005541A (ko) 치환된 벤조에이트 유도체
KR920700669A (ko) 치료시 비사이클릭 화합물의 n-이미다졸릴 유도체 및 사이클로스포린의 혼합 용도
TH35867A (th) สารสูตรผสมที่ปรับปรุงชนิดใหม่สำหรับรักษาสภาวะลิ่มเลือดจุกหลอดเลือด
DE60034580D1 (de) Peptid zur behandlung von nervenerkrankungen
KR890005123A (ko) 세펨 화합물 및 이의 제조방법

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties